Children's Oncology Group's 2023 blueprint for research: Developmental therapeutics

Elizabeth Fox; D. Williams Parsons; Brenda J. Weigel

doi:10.1002/pbc.30563

Children's Oncology Group's 2023 blueprint for research: Developmental therapeutics

Elizabeth Fox, D. Williams Parsons, Brenda J. Weigel

Pediatrics - Hematology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The Developmental Therapeutics Committee (DVL) identifies and develops new agents and treatment strategies for children/adolescents with cancer, through clinical and translational research. DVL has focused on evaluating the activity of targeted therapy and has evolved from trials with multiple histology strata to biomarker-selected phase 2 trials. These trials have included single-agent studies to evaluate agents such as cabozantinib in multi-disease cohorts, to trametinib, larotrectinib, and lorvotuzumab in disease-specific cohorts, as well as the pediatric Molecular Analysis for Therapy Choice (MATCH) study including multiple single agents targeted for biomarker-selected pediatric tumors. The ongoing vision and direction of DVL is to support the disease committees of COG to develop novel agents and combinations to advance the care of children with cancer.

Original language	English (US)
Article number	e30563
Journal	Pediatric Blood and Cancer
Volume	70
Issue number	S6
DOIs	https://doi.org/10.1002/pbc.30563
State	Published - Sep 2023

Bibliographical note

Publisher Copyright:
© 2023 Wiley Periodicals LLC.

Keywords

phase 2
precision medicine
trial design

PubMed: MeSH publication types

Journal Article
Research Support, N.I.H., Extramural

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1002/pbc.30563

OpenUrl availability

Full text

Cite this

@article{408c1f40fb024820bcd08dca647889c5,

title = "Children's Oncology Group's 2023 blueprint for research: Developmental therapeutics",

abstract = "The Developmental Therapeutics Committee (DVL) identifies and develops new agents and treatment strategies for children/adolescents with cancer, through clinical and translational research. DVL has focused on evaluating the activity of targeted therapy and has evolved from trials with multiple histology strata to biomarker-selected phase 2 trials. These trials have included single-agent studies to evaluate agents such as cabozantinib in multi-disease cohorts, to trametinib, larotrectinib, and lorvotuzumab in disease-specific cohorts, as well as the pediatric Molecular Analysis for Therapy Choice (MATCH) study including multiple single agents targeted for biomarker-selected pediatric tumors. The ongoing vision and direction of DVL is to support the disease committees of COG to develop novel agents and combinations to advance the care of children with cancer.",

keywords = "phase 2, precision medicine, trial design",

author = "Elizabeth Fox and Parsons, {D. Williams} and Weigel, {Brenda J.}",

note = "Publisher Copyright: {\textcopyright} 2023 Wiley Periodicals LLC.",

year = "2023",

month = sep,

doi = "10.1002/pbc.30563",

language = "English (US)",

volume = "70",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "S6",

}

TY - JOUR

T1 - Children's Oncology Group's 2023 blueprint for research

T2 - Developmental therapeutics

AU - Fox, Elizabeth

AU - Parsons, D. Williams

AU - Weigel, Brenda J.

PY - 2023/9

Y1 - 2023/9

N2 - The Developmental Therapeutics Committee (DVL) identifies and develops new agents and treatment strategies for children/adolescents with cancer, through clinical and translational research. DVL has focused on evaluating the activity of targeted therapy and has evolved from trials with multiple histology strata to biomarker-selected phase 2 trials. These trials have included single-agent studies to evaluate agents such as cabozantinib in multi-disease cohorts, to trametinib, larotrectinib, and lorvotuzumab in disease-specific cohorts, as well as the pediatric Molecular Analysis for Therapy Choice (MATCH) study including multiple single agents targeted for biomarker-selected pediatric tumors. The ongoing vision and direction of DVL is to support the disease committees of COG to develop novel agents and combinations to advance the care of children with cancer.

AB - The Developmental Therapeutics Committee (DVL) identifies and develops new agents and treatment strategies for children/adolescents with cancer, through clinical and translational research. DVL has focused on evaluating the activity of targeted therapy and has evolved from trials with multiple histology strata to biomarker-selected phase 2 trials. These trials have included single-agent studies to evaluate agents such as cabozantinib in multi-disease cohorts, to trametinib, larotrectinib, and lorvotuzumab in disease-specific cohorts, as well as the pediatric Molecular Analysis for Therapy Choice (MATCH) study including multiple single agents targeted for biomarker-selected pediatric tumors. The ongoing vision and direction of DVL is to support the disease committees of COG to develop novel agents and combinations to advance the care of children with cancer.

KW - phase 2

KW - precision medicine

KW - trial design

UR - http://www.scopus.com/inward/record.url?scp=85164776384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85164776384&partnerID=8YFLogxK

U2 - 10.1002/pbc.30563

DO - 10.1002/pbc.30563

M3 - Article

C2 - 37430453

AN - SCOPUS:85164776384

SN - 1545-5009

VL - 70

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - S6

M1 - e30563

ER -

Children's Oncology Group's 2023 blueprint for research: Developmental therapeutics

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this